# JNJ Q3 Earnings Drop Amid Talc Litigation

> Johnson & Johnson's Q3 earnings fell as talc litigation costs and medtech slowdown hit.
- Title: JNJ Q3 Earnings Drop Amid Talc Litigation · Seekingalpha
- Summary: Johnson & Johnson's Q3 earnings fell as talc litigation costs and medtech slowdown hit. Johnson & Johnson reported 6% revenue growth but 7.5% lower earnings…
- Keywords: johnson and johnson, talc litigation, q3 2026, medtech, earnings, revenue growth, eps decline, money, business, JNJ, Drop, Talc
- Source: Seekingalpha — https://seekingalpha.com/article/4953865-johnson-and-johnson-q3-talc-resolution-offer-impacts-earnings-medtech-slows-growth
- Author: Edmund Ingham
- Published: 2026-10-13T17:11:04+00:00
- Read time: 1 min
- Topics: johnson and johnson, talc litigation, q3 2026, medtech, earnings, revenue growth, eps decline, money, business
## Q3 Results
Johnson & Johnson reported 6% revenue growth to $25.4bn but 7.5% lower earnings year-on-year.
## Talc Litigation Plan
Jnj set aside $5.5bn for talc litigation aiming for 95% plaintiff participation.
## MedTech Underperformance
Medtech division slowed growth as orthopedics unit spin-off planned.
## Key takeaway

Johnson & Johnson reported 6% revenue growth but 7.5% lower earnings due to talc litigation costs and medtech underperformance.